{"groups":[{"description":"Drug: Pomalidomide Cohort 1 = 2 mg/day, Days 1-28\n\nDrug: Dexamethasone 10-20 mg on days 1, 8, 15, and 22","id":"FG000","title":"Experimental: Phase I - Cohort 1 (Pomalidomide 2mg)"},{"description":"Drug: Pomalidomide Cohort 12= 3 mg/day, Days 1-28\n\nDrug: Dexamethasone 10-20 mg on days 1, 8, 15, and 22","id":"FG001","title":"Experimental: Phase I - Cohort 2 (Pomalidomide 3mg)"},{"description":"Drug: Pomalidomide Cohort 3 = 4 mg/day, Days 1-28\n\nDrug: Dexamethasone 10-20 mg on days 1, 8, 15, and 22","id":"FG002","title":"Experimental: Phase I - Cohort 3 (Pomalidomide 4mg)"},{"description":"Drug: Pomalidomide Expansion Phase - Maximum Tolerated Dose = 4 mg/day, Days 1-28\n\nDrug: Dexamethasone 10-20 mg on days 1, 8, 15, and 22","id":"FG003","title":"Experimental: Phase II Expansion- Maximum Tolerated Dose"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"12"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"12"}],"type":"Dose Limiting Toxicity"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"6"}],"type":"Response to Maximal Tolerated Dose"},{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"10"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Protocol was open to accrual between January 2012 and August 2016. Participants were recruited from within the amyloidosis clinic within Boston Medical Center."}